Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis
about
Inhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and functionThe Role of Serine Proteases and Antiproteases in the Cystic Fibrosis LungEstrogen receptor-alpha as a drug target candidate for preventing lung inflammation.Liver transplantation for hepatic cirrhosis in cystic fibrosis.Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosisBody mass index reference curves for the UK, 1990Reduced upper airway nitric oxide in cystic fibrosis.Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis.Contribution of genetic factors other than CFTR to disease severity in cystic fibrosisMacrolides in cystic fibrosis: is there a role?Lung inflammation as a therapeutic target in cystic fibrosis.Toward the pharmacogenomics of cystic fibrosis--an update.Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis.A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.Sputum biomarkers of inflammation in cystic fibrosis lung diseaseUpdate on gene modifiers in cystic fibrosis.Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing for Cystic Fibrosis.Assessment and monitoring of cystic fibrosis lung disease in infants and young children.A melanin pigment purified from an epidemic strain of Burkholderia cepacia attenuates monocyte respiratory burst activity by scavenging superoxide anion.Lipopolysaccharide (LPS) from Burkholderia cepacia is more active than LPS from Pseudomonas aeruginosa and Stenotrophomonas maltophilia in stimulating tumor necrosis factor alpha from human monocytes.Bioactive tumor necrosis factor in the sputa of cystic fibrosis patients.Burkholderia (basonym Pseudomonas) cepacia binding to lipid receptors.Antiproteases as therapeutics to target inflammation in cystic fibrosis.Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease.Faecal interleukin-8 and tumour necrosis factor-alpha concentrations in cystic fibrosis.Corticosteroid treatment in cystic fibrosis.Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.Deficiency of the mannan-binding lectin pathway of complement and poor outcome in cystic fibrosis: bacterial colonization may be decisive for a relationship.Controlled Trial of Inhaled Budesonide in Patients with Cystic Fibrosis and Chronic BronchopulmonaryPseudomonas aeruginosaInfection
P2860
Q26799406-47737B99-BCD8-496E-83C6-47AEE26482E4Q26799771-DD6C0C40-6A4E-456C-8C6A-3159EB04AFEDQ33577529-8B31B063-1F8D-4E77-B8AF-14A1A79779C9Q33625138-E6274AC0-96DE-4FB3-8B1F-614B9B5B9A36Q33997692-14C82E5F-AEA3-4469-A69A-B550187AB49EQ34796304-5ABBB279-A947-41DB-94A0-70B36A2A317BQ34799884-FE707CE4-3DC6-477D-B768-D56B76CC92FBQ35256369-EB11B94D-7238-470D-A1A2-B6BAAA667152Q35532239-388107EB-7A40-4940-896A-1E297F9FAA18Q35627801-30C128DD-617C-492B-B6FA-2F04709B583CQ35894285-552288AA-61C2-460A-ABF2-75EE8472A086Q35911156-8D35304F-D0B9-4C78-894B-72C05361B99FQ36511963-CA6FCA42-05F6-4810-BBEE-5163CB675279Q36584924-0EAFB00A-871E-4997-BA70-F4340AA69B26Q36891552-2CCD8B22-9657-421D-AB9A-76BC6FE15CFFQ37277637-635D83D0-E15D-4D04-AB28-D61C00F69C04Q37470271-37543C3C-682B-439D-99FF-314E6B4B7AD4Q37700876-4C0175FC-9A1E-4E4B-B1AD-0356DFCFB137Q37754879-F4DCB472-5B34-4AF5-8F6A-D84990996FE1Q39509776-9FCBE1D4-7174-4BC0-8537-51F4F38C3742Q39510228-BCB9F448-0726-4B10-9A01-7B5C66D90807Q39809840-DB9A6C69-0850-4198-BE93-E08D945DACE9Q39824731-04D8F097-CC18-46E3-A179-075B9B43094DQ40363808-FBCA742C-400E-42C3-8381-FA1E7C992A1AQ41688386-B579BE38-208B-4429-82B2-2D5637959869Q41912129-F5ED7A73-6901-4B2D-A96F-C29A7ECADB2CQ41968290-60BA0A01-C5DD-4036-A9B7-3F2CBAB777DFQ45198841-F2E57201-A73C-41E7-81DA-EFD6A4BD3326Q45227453-2CA5A118-75B2-4105-9A64-EBBFFF27F824Q57638396-B467B356-717E-4571-AA03-EDB905632F68
P2860
Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis
@ast
Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis
@en
type
label
Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis
@ast
Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis
@en
prefLabel
Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis
@ast
Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis
@en
P2093
P2860
P921
P356
P1476
Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis
@en
P2093
P2860
P304
P356
10.1136/ADC.68.3.389
P407
P577
1993-03-01T00:00:00Z